Ubs Asset Management Americas Inc Kymera Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 404,667 shares of KYMR stock, worth $12.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
404,667
Previous 428,529
5.57%
Holding current value
$12.2 Million
Previous $20.3 Million
19.74%
% of portfolio
0.0%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding KYMR
# of Institutions
185Shares Held
65.5MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$208 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$181 Million2.67% of portfolio
-
Wellington Management Group LLP Boston, MA5.31MShares$161 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$156 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$156 Million3.02% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.65B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...